DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/3h43rh/neurology_drug) has announced the addition of the "Neurology Drug Report 2014" report to their offering.
This report for the first time identifies and profiles 480 Active Neurology focused Drug Development companies from 31 countries worldwide, developing 801 neurological disorders targeting drugs. It evaluates 16 major neurological indications drug development pipeline and analysis it to provide thousands of active clinical trials information; emerging drug targets, molecule types etc. Thus all together brings the most updated and robust information at the fingertips. It creates immense authentic knowledge-base (all information with references) on hundreds of proprietary technologies, M&A deals and partnering occurring in domain in last 10 years.
The 16 Major Indications detailed coverage in the report includes- Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis, Schizophrenia, Major Depressive Disorder, Amyotrophic Lateral Sclerosis, Ischemic and Hemorrhagic Stroke, Huntington's Disease, Epilepsy, Pain (Migraine, Neurotropic and Post Hepatic Neuralgia), Neurological Trauma, Anxiety Disorders, ADHD, Addiction, Autism Spectrum Disorder, Bipolar Disorder and other Rare Neurological disorder.
Report covers each individual indication Epidemiology, Treatment options, Top selling drugs and their sales, indication Market size and forecast with detailed drug development Pipeline Analysis covering all Monoclonal Antibodies, Vaccines, Stem Cell Therapies, and Medical Devices in development, it also covers promising technologies and top drug development targets for the indication. Thus making it a versatile Comprehensive Report for Decision-Making.
A Single Innovative and Unique Report provide Answers to Many:
- It provides immense opportunities in identifying emerging cancer companies. It covers active 272 clinical, 208 Preclinical and Discovery stage companies along with their current partners, technologies and cancer drug pipeline.
- It provides LinkedIn and E-mail IDs of all decision makers in individual clinical companies. These thousand's of focused links helps in saving time and linking to right person to further work on finer details.
- 16 Major Neurological Indication's Individual Drug Development Pipeline and its Analysis, Market Size and Forecast.
- Rare Neurological Indications Drug development pipelines are also included, separately.
- All Finer Details are further elaborated in the individual 480 Companies Profiles, all written in form of mini reports.
- Offers complete and focused lead identification details for Biosuppliers /CROs.
- The complete 532 Pages report is highly interlinked with all Clinical Trials numbers and last updated status.
- The Text is supplemented with 98 Tables and 36 Figures/Info-graphics.
For more information visit http://www.researchandmarkets.com/research/3h43rh/neurology_drug
